Northwest Biotherapeutics Announces Director and Executive Changes
Ticker: NWBO · Form: 8-K · Filed: 2024-03-22T00:00:00.000Z
Sentiment: neutral
Topics: management-change, compensation
TL;DR
NWBO board shakeup & exec comp changes effective March 18.
AI Summary
Northwest Biotherapeutics, Inc. announced on March 18, 2024, changes in its board of directors and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its key executives. These changes are effective as of March 18, 2024.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, potentially impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Northwest Biotherapeutics, Inc. (company) — Registrant
- March 18, 2024 (date) — Effective date of reported changes
FAQ
Who specifically departed from the board or officer positions?
The filing indicates the departure of 'certain officers' and 'directors' but does not name them in this section.
Who were the newly elected directors?
The filing states that directors were elected but does not provide their names in this section.
What specific changes were made to executive compensatory arrangements?
The filing mentions adjustments to compensatory arrangements for certain officers but does not detail the specifics of these changes.
What is the effective date of these reported changes?
The earliest event reported is dated March 18, 2024, and the filing is as of this date.
What is the primary business of Northwest Biotherapeutics, Inc.?
Northwest Biotherapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-03-22 16:30:39
Key Financial Figures
- $0.001 — registered: Common Stock, par value, $0.001 per share NWBO OTCQB Indicate by
Filing Documents
- tm249577d1_8k.htm (8-K) — 22KB
- 0001104659-24-037901.txt ( ) — 188KB
- nwbo-20240318.xsd (EX-101.SCH) — 3KB
- nwbo-20240318_lab.xml (EX-101.LAB) — 33KB
- nwbo-20240318_pre.xml (EX-101.PRE) — 22KB
- tm249577d1_8k_htm.xml (XML) — 3KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director The Board appointed Pat Sarma as a Class II director on March 18, 2024, and also appointed him to the Audit, Compensation, and Conflicts Committees of the Board. There were no arrangements between Mr. Sarma and other persons pursuant to which he was appointed as a director. There are no related-party transactions in which he or any immediate member of his family has an interest that would require disclosure under Item 404(a) of Regulation S-K. As an independent member of the Board of Directors, he will be entitled to receive compensation on the same basis as the Company's other non-employee directors. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INC. Date: March 22, 2024 By: /s/ Linda Powers Name: Linda Powers Title: Chief Executive Officer and Chairman